{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:08:10Z","timestamp":1698790090010},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,4,25]],"date-time":"2003-04-25T00:00:00Z","timestamp":1051228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s00280-003-0570-7","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T02:55:52Z","timestamp":1576119352000},"page":"483-487","source":"Crossref","is-referenced-by-count":5,"title":["Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice"],"prefix":"10.1007","volume":"51","author":[{"given":"Joel M.","family":"Reid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Squillace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Ames","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,4,25]]},"reference":[{"key":"0570_CR1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","volume":"27","author":"Bradner","year":"2001","unstructured":"Bradner WT (2001) Mitomycin C: a clinical update. Cancer Treat Rev 27:35","journal-title":"Cancer Treat Rev"},{"key":"0570_CR2","first-page":"3248","volume":"58","author":"Fuse","year":"1998","unstructured":"Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58:3248","journal-title":"Cancer Res"},{"key":"0570_CR3","unstructured":"Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, p 409"},{"key":"0570_CR4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"H\u00c3\u00b6ckel","year":"2001","unstructured":"H\u00f6ckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266","journal-title":"J Natl Cancer Inst"},{"key":"0570_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0360-3016(98)00310-1","volume":"42","author":"Lee","year":"1998","unstructured":"Lee DJ, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, Harvey E, Groves E (1998) Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 42:811","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"0570_CR6","first-page":"S267","volume":"74","author":"Papadopoulou","year":"1996","unstructured":"Papadopoulou MV, Ji M, Bloomer WD (1996) THNLA-1 as radio\/chemosensitizer of EMT-6 tumours in mice. Br J Cancer 74:S267","journal-title":"Br J Cancer"},{"key":"0570_CR7","first-page":"425","volume":"8","author":"Papadopoulou","year":"1996","unstructured":"Papadopoulou MV, Ji M, Rao MK, Bloomer WD (1996) 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res 8:425","journal-title":"Oncol Res"},{"key":"0570_CR8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0360-3016(98)00333-2","volume":"42","author":"Papadopoulou","year":"1998","unstructured":"Papadopoulou MV, Ji M, Bloomer WD (1998) NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 42:775","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"0570_CR9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3727\/096504001108747774","volume":"12","author":"Papadopoulou","year":"2000","unstructured":"Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine. Oncol Res 12:325","journal-title":"Oncol Res"},{"key":"0570_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3727\/096504001108747675","volume":"12","author":"Papadopoulou","year":"2000","unstructured":"Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12:185","journal-title":"Oncol Res"},{"key":"0570_CR11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s002800100290","volume":"48","author":"Papadopoulou","year":"2001","unstructured":"Papadopoulou MV, Ji M, Bloomer WD (2001) Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 48:160","journal-title":"Cancer Chemother Pharmacol"},{"key":"0570_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-002-0491-x","volume":"50","author":"Papadopoulou","year":"2002","unstructured":"Papadopoulou MV, Ji M, Ji X, Bloomer WD (2002) Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine. Cancer Chemother Pharmacol 50:291","journal-title":"Cancer Chemother Pharmacol"},{"key":"0570_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0360-3016(98)00302-2","volume":"42","author":"Rauth","year":"1998","unstructured":"Rauth AM, Melo T, Misra V (1998) Bioreductive therapies: an overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 42:755","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"0570_CR14","first-page":"31","volume":"3","author":"Senan","year":"1997","unstructured":"Senan S, Rampling R, Graham MA, Wilson P, Robin H Jr, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, Kaye SB (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3:31","journal-title":"Clin Cancer Res"},{"key":"0570_CR15","first-page":"3339","volume":"50","author":"Teicher","year":"1990","unstructured":"Teicher BA, Holden SA, Al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50:3339","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-003-0570-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-003-0570-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-003-0570-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T02:55:58Z","timestamp":1576119358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-003-0570-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,25]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["0570"],"URL":"https:\/\/doi.org\/10.1007\/s00280-003-0570-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,25]]}}}